We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Large GWAS Study Finds DNA Variants Linked to Risk of Developing Breast Cancer

By LabMedica International staff writers
Posted on 13 Jan 2020
Print article
Image: Micrograph showing a lymph node invaded by ductal breast cancer and with extranodal extension of the tumor. The dark purple (center) shows lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is the ductal breast cancer (Photo courtesy of Wikimedia Commons)
Image: Micrograph showing a lymph node invaded by ductal breast cancer and with extranodal extension of the tumor. The dark purple (center) shows lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is the ductal breast cancer (Photo courtesy of Wikimedia Commons)
A large multinational study identified more than 350 DNA variants associated with the more than 150 regions of the genome known to be linked to the risk for developing breast cancer.

Investigators at more than 450 departments and institutions worldwide, including the University of Cambridge (United Kingdom) and the Wellcome Sanger Institute (Hinxton, United Kingdom), collaborated to compare the DNA of 110,000 breast cancer patients against that of some 90,000 healthy controls.

Previous genome-wide association studies (GWAS), which compared the DNA of patients against that of healthy controls, found around 150 regions of the genome that clearly affected breast cancer risk. The use of advanced gene mapping techniques in the current study enabled investigators to identify 352 risk variants within these regions. So far, it is not yet clear how many genes these variants target, but the investigators have identified 191 genes with reasonable confidence.

In the majority of cases, the variants affected gene expression, how active a particular gene was and how much of a particular protein it created, rather than altering the type of protein coded by the gene. Of the newly-discovered genetic variants, about a third predispose women towards developing hormone-responsive breast cancer, the type of disease found in 80% of breast cancer patients. These tumors respond to hormonal treatments such as tamoxifen. In contrast, 15% of the genetic variants predispose women to the rarer estrogen-receptor-negative type of breast cancer.

"We know from previous studies that variants across our DNA contribute towards breast cancer risk, but only rarely have scientists have been able to identify exactly which genes are involved," said first author Dr. Laura Fachal researcher in human genetics at the Wellcome Sanger Institute. "We need this information as it gives us a better clue to what is driving the disease and hence how we might treat or even prevent it."

"This incredible haul of newly-discovered breast cancer genes provides us with many more genes to work on, most of which have not been studied before," said senior author Dr. Alison Dunning, reader in molecular cancer genetics at the University of Cambridge. "It will help us build up a much more detailed picture of how breast cancer arises and develops. But the sheer number of genes now known to play a role emphasizes how complex the disease is."

The breast cancer genome-wide association study was published in the January 7, 2020, online edition of the journal Nature Genetics

Related Links:
University of Cambridge
Wellcome Sanger Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more